Simpler Grants.gov #FOR-CA-25-086

NCI SBIR Phase IIB Bridge Awards for Cancer Technology Commercialization

This opportunity is a forecasted Notice of Funding Opportunity (NOFO) from the National Cancer Institute (NCI) under the National Institutes of Health (NIH) to support the commercialization of cancer-relevant technologies developed by small businesses. - Government Buyer: - National Institutes of Health (NIH) - National Cancer Institute (NCI) - Eligible Applicants: - Small business concerns with prior SBIR or STTR Phase II awards from any Federal agency - Nonprofits, government entities, and educational institutions may also be eligible - Products/Services Requested: - No specific products, OEMs, or vendors are named - Funding is for research and development projects in cancer technology commercialization - Projects may be at preclinical or clinical stages; clinical trials are optional - Unique/Notable Requirements: - Applicants must secure independent third-party investor or strategic partner funding equal to or greater than the NCI funds requested - A detailed Commercialization Plan is required - The funding instrument is a grant, not a contract or product procurement - No part numbers, quantities, or specific technical products are listed, as this is a grant for R&D, not a product purchase.

Description

The National Cancer Institute (NCI) plans to publish a Notice of Funding Opportunity (NOFO) to solicit Small Business Innovation Research (SBIR) applications from small business concerns seeking additional funding to support the next stage of development for cancer-relevant projects previously funded under SBIR or STTR Phase II awards. The NOFO aims to facilitate the transition of these projects to commercialization by promoting partnerships with third-party investors or strategic partners. Applicants must submit a Commercialization Plan detailing any independent third-party funding secured or anticipated, which should be equal to or greater than the NCI funds requested. Proposed projects may address preclinical and/or clinical stages of technology development, with clinical trials optional.

View original listing